MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)

Trial Profile

MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Act.in.sarc
  • Sponsors Nanobiotix; PharmaEngine
  • Most Recent Events

    • 26 Dec 2017 According to a Nanobiotix media release, the Company expects to present the results of this trial in Q2 2018, after last patient has been treated and the analysis is complete.
    • 13 Nov 2017 Results of antitumor immunity analysis presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2017, according to a Nanobiotix media release.
    • 23 Oct 2017 According to a Nanobiotix media release, the last patients are expected to start their treatment in two to three weeks. Results of this trial expected in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top